NEW YORK (360Dx) – Mologic is expanding into the US market and targeting the near-term commercialization of rapid respiratory diagnostics for use in the home.

Simultaneously, the Bedford, UK-based company is developing rapid sepsis diagnostics for use in primary care and emergency room settings.

The firm is taking its in-home monitoring systems for chronic obstructive pulmonary disease (COPD) and cystic fibrosis and professional-use sepsis confirmation system through clinical trials, and it anticipates launching them in the next couple of years in the US and Europe.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.